REGN7508 for Cancer-Related Blood Clots

(ROXI-CAT-I Trial)

This trial tests a new drug, REGN7508, to determine its ability to prevent blood clots in people with solid tumors undergoing cancer treatment. It compares the drug to a placebo (a harmless pill with no active medicine) to assess its effectiveness. The study also examines side effects, the drug's movement in the body, and whether the body produces antibodies against it. People diagnosed with advanced cancer and at higher risk for blood clots might be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking advancements in cancer treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that REGN7508 is generally safe for patients. In earlier studies, no treatment-related deaths occurred among those taking REGN7508. This suggests the treatment is reasonably safe for preventing blood clots, even in people with cancer or those undergoing surgery. While side effects can occur with any medication, these findings provide reassurance about the safety of REGN7508.¹²³⁴⁵

Unlike the standard treatments for cancer-related blood clots, which typically involve anticoagulants like warfarin or direct oral anticoagulants (DOACs), REGN7508 offers a novel approach. This experimental drug is designed to specifically target and address the blood clotting process associated with cancer, potentially offering a more focused treatment. Researchers are excited because REGN7508 may provide better outcomes with fewer side effects, addressing a significant need for safer, more effective options in managing blood clots linked to cancer.

Research has shown that REGN7508 effectively prevents blood clots in people with cancer. In one study, only 7% of participants taking REGN7508 developed blood clots, compared to 21% for those on enoxaparin and 12% for those on apixaban. This indicates that REGN7508 is more effective at preventing blood clots than these other treatments. In this trial, participants will receive either REGN7508 or a placebo to further evaluate its effectiveness and safety. The drug has successfully prevented a specific type of blood clot called venous thromboembolism. Researchers aim to determine whether it can reduce the risk of blood clots without increasing side effects. Early results suggest it could be a promising option for people with cancer who are at risk for blood clots.¹²⁴⁶⁷